Invivyd(IVVD)
NEW HAVEN, CTBiotechnology
Focus: Invivyd is a public biotechnology company specializing in therapeutic antibodies, primarily focused on infectious disease treatments with a concentrated pipeline in COVID-19 antivirals. The company operates as a lean, R&D-intensive platform with $25M in FY2025 revenue against $137M in R&D spending.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
17-16 this month
Cooling — net -16 jobs in 30d
6 added, 22 removed. Slower than typical.
Should You Work at Invivyd?
AI assessmentInvivyd offers high-risk, high-upside antibody development experience for risk-tolerant professionals, but significant financial distress and pipeline concentration demand caution about job security and equity value.
Why Work Here
- Pioneer a therapeutic antibody platform in infectious disease with multiple Phase 3 programs advancing toward potential commercialization
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$25M
Pipeline & Clinical Trials
VYD222
COVID-19Clinical Trials (1)
NCT06004128Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
N/AHelp build intelligence for Invivyd
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.